Entresto Shines Brightly Among New Launches In India
Novartis’ Entresto has had a strong run in India, with two second brands in tow, while itraconazole and azilsartan therapies are among the other recent introductions that have gained traction in a competitive market.
You may also be interested in...
Sacubitril/valsartan combination sales surge in India driving growth in the cardiac care segment even as Novartis and challenger Natco slug it out in court over alleged patent infringement charges.
India has seen an uptick in in-licensing deals, with robust growth in the number of novel drugs in such arrangements delivering gains for both the domestic partner and innovator company.
Paul Hudson, CEO, Novartis Pharmaceuticals, was recently in India along with the executive leadership team of the Swiss multinational. In a wide-ranging exclusive interview with Scrip, he discussed Cosentyx’s edge over its competition, Entresto’s “incredibly bright future”, including in emerging markets like India, and why transparency on the scale of rebates in the US is "overdue."